Bibliographie

[1] Levtchenko E. Cystinose. ORPHANET; 2020. https://www.orpha.net/fr/disease/detail/213.

[2] Gahl WA, Kuehl EM, Iwata F, et al. Corneal crystals in nephropathic cystinosis : Natural history and treatment with cysteamine eyedrops. Mol Genet Metab 2000;71(1-2):100–20.

[3] Labbé A, Niaudet P, Loirat C, et al. In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis. Ophthalmology 2009;116(5):870–6.

[4] Liang H, Baudouin C, Tahiri Joutei Hassani R, et al. Photophobia and corneal crystal density in nephropathic cystinosis : an in vivo confocal microscopy and anterior-segment optical coherence tomography study. Invest ophthalmol Vis Sci 2015;56(5):3218–25.

[5] Liang H, Labbé A, Baudouin C, et al. Long-term follow-up of cystinosis patients treated with 0.55 % cysteamine hydrochloride. Br J Ophthalmol 2021;105(5):608–13.

[6] Liang H, Labbé A, Le Mouhaër J, et al. A new viscous cysteamine eye drops treatment for ophthalmic cystinosis : an open-label randomized comparative phase III pivotal study. Invest Ophthalmol Vis Sci 2017;58(4):2275–83.

[7] McGrath O, Sornalingam K, Aslam T, et al. Changes in corneal clouding over time in patients with mucopolysaccharidosis. Cornea 2023;42(8):992–9.

[8] McGrath O, Au L, Ashworth J. Management of corneal clouding in patients with mucopolysaccharidosis. J Clin Med 2021;10(15)3263.

[9] Hallal Jr R, Armstrong GW, Pineda R. Long-term outcomes of big bubble deep anterior lamellar keratoplasty in mucopolysaccharidoses : A retrospective case series and review of the literature. Cornea 2022;41(7):809–14.

[10] Elbaz U, Kirwan C, Shen C, et al. Avoiding big bubble complications : outcomes of layer-by-layer deep anterior lamellar keratoplasty in children. Br J Ophthalmol 2018;102(8):1103–8.

[11] Saeedi R, Li M, Frohlich J. A review on lecithin : cholesterol acyltransferase deficiency. Clin Biochem 2015;48(7-8):472–5.

[12] Palmiero PM, Sbeity Z, Liebmann J, et al. In vivo imaging of the cornea in a patient with lecithin-cholesterol acyltransferase deficiency. Cornea 2009;28(9):1061–4.

[13] Protocole national de diagnostic et de soins : maladie de Wilson. HAS; 2022.

[14] Członkowska A, Litwin T, Dusek P, et al. Wilson disease Nat Rev Dis Primers 2018;4(1):21.

[15] Poujois A, Woimant F, Samson S, et al. Characteristics and prevalence of Wilson's disease : a 2013 observational population-based study in France. Clin Res Hepatol Gastroenterol 2018;42(1):57–63.

[16] Chevalier K, Mauget-Faÿsse M, Vasseur V, et al. Eye involvement in Wilson's disease : a review of the literature. J Clin Med 2022;11(9):25–8.

[17] Couchonnal E, Lion-François L, Guillaud O, et al. Pediatric Wilson's disease : Phenotypic, genetic characterization and outcome of 182 children in France. J Pediatr Gastroenterol Nutr 2021;73(4):e80–6.

[18] Broniek-Kowalik K, Dzieżyc K, Litwin T, et al. Anterior segment optical coherence tomography (AS-OCT) as a new method of detecting copper deposits forming the Kayser-Fleischer ring in patients with Wilson disease. Acta Ophthalmol 2019;97(5):e757–60.

[19] Ingster-Moati I, Bui Quoc E, Pless M, et al. Ocular motility and Wilson's disease : a study on 34 patients. J Neurol Neurosurg Psychiatry 2007;78(11):1199–201.

[20] Protocole national de diagnostic et de soins : maladie de Fabry. HAS; 2021.

[21] Samiy N. Ocular features of Fabry disease : diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 2008;53(4):416–23.

[22] Roche O, Orssaud C, Germain D, et al. Pediatric aspects of Fabry's disease. Arch Pediatr 2007;14(7):909–14.

[23] Sivley MD, Wallace EL, Warnock DG, et al. Conjunctival lymphangiectasia associated with classic Fabry disease. Br J Ophthalmol 2018;102(1):54–8.

[24] Moshirfar M, Bundogji N, Tukan AN, et al. Implications of corneal refractive surgery in patients with Fabry disease. Ophthalmol Ther 2022;11(3):925–9.

[25] Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia : a review. Pediatr Dev Pathol 2001;4(3):212–21.

[26] Macsai MS, Schwartz TL, Hinkle D, et al. Tyrosinemia type II : nine cases of ocular signs and symptoms. Am J Ophthalmol 2001;132(4):522–7.

[27] Protocole national de diagnostic et de soins : Tyrosinémie type 1 (HT-1). HAS; 2022.

[28] Gulmez Sevim D, Gumus K, Cavanagh HD. Corneal pseudodendritic lesions masquerading as herpetic keratitis in a patient with tyrosinemia type I. Eye Contact Lens 2017;43(3):e7–9.

[29] Schauwvlieghe PP, Jaeken J, Kestelyn P, et al. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC. Cornea 2013;32(1):91–4.

[30] Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol 2002;134(2):266–8.

[31] Martin GC, de Lonlay P, Chapron T, et al. Bilateral dendriform ulcer leading to an early diagnosis of tyrosinemia type 2. J AAPOS 2020;24(2):120–2.